A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity. 2013

David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
Centre for Computational Science, Department of Chemistry, University College London, United Kingdom.

Reverse transcriptase (RT) plays an essential role in HIV-1 replication, and inhibition of this enzyme is a key component of HIV-treatment. However, the use of RT inhibitors can lead to the emergence of drug-resistant variants. Until recently, most clinically relevant resistance mutations were found in the polymerase domain of RT. Lately, an increasing number of resistance mutations has been identified in the connection and RNaseH domain. To further explore the role of these domains we analyzed the complete RT sequence of HIV-1 subtype B patients failing therapy. Position A/T400 in the connection subdomain is polymorphic, but the proportion of T400 increases from 41% in naïve patients to 72% in patients failing therapy. Previous studies suggested a role for threonine in conferring resistance to nucleoside RT inhibitors. Here we report that T400 also mediates resistance to non-nucleoside RT inhibitors. The susceptibility to NVP and EFV was reduced 5-fold and 2-fold, respectively, in the wild-type subtype B NL4.3 background. We show that substitution A400T reduces the RNaseH activity. The changes in enzyme activity are remarkable given the distance to both the polymerase and RNaseH active sites. Molecular dynamics simulations were performed, which provide a novel atomistic mechanism for the reduction in RNaseH activity induced by T400. Substitution A400T was found to change the conformation of the RNaseH primer grip region. Formation of an additional hydrogen bond between residue T400 and E396 may play a role in this structural change. The slower degradation of the viral RNA genome may provide more time for dissociation of the bound NNRTI from the stalled RT-template/primer complex, after which reverse transcription can resume.

UI MeSH Term Description Entries
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D017434 Protein Structure, Tertiary The level of protein structure in which combinations of secondary protein structures (ALPHA HELICES; BETA SHEETS; loop regions, and AMINO ACID MOTIFS) pack together to form folded shapes. Disulfide bridges between cysteines in two different parts of the polypeptide chain along with other interactions between the chains play a role in the formation and stabilization of tertiary structure. Tertiary Protein Structure,Protein Structures, Tertiary,Tertiary Protein Structures
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D054309 Ribonuclease H, Human Immunodeficiency Virus A ribonuclease activity that is a component of the HIV REVERSE TRANSCRIPTASE. It removes the RNA strand of the RNA-DNA heteroduplex produced by reverse transcription. Once the RNA moiety is removed a double stranded DNA copy of the HIV RNA can be synthesized. RNAse H, HIV,Ribonuclease H, HIV,HIV RNAse H,HIV Ribonuclease H
D056004 Molecular Dynamics Simulation A computer simulation developed to study the motion of molecules over a period of time. Molecular Dynamics Simulations,Molecular Dynamics,Dynamic, Molecular,Dynamics Simulation, Molecular,Dynamics Simulations, Molecular,Dynamics, Molecular,Molecular Dynamic,Simulation, Molecular Dynamics,Simulations, Molecular Dynamics
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D023281 Genomics The systematic study of the complete DNA sequences (GENOME) of organisms. Included is construction of complete genetic, physical, and transcript maps, and the analysis of this structural genomic information on a global scale such as in GENOME WIDE ASSOCIATION STUDIES. Functional Genomics,Structural Genomics,Comparative Genomics,Genomics, Comparative,Genomics, Functional,Genomics, Structural
D024882 Drug Resistance, Viral The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation. Antiviral Drug Resistance,Antiviral Drug Resistances,Drug Resistances, Viral

Related Publications

David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
May 2015, The Journal of antimicrobial chemotherapy,
David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
December 2010, The Journal of biological chemistry,
David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
December 2012, Cellular and molecular biology (Noisy-le-Grand, France),
David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
November 2011, Antiviral research,
David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
August 2008, Proceedings of the National Academy of Sciences of the United States of America,
David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
December 2016, Journal of biomolecular NMR,
David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
December 2017, Journal of biomolecular NMR,
David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
September 2011, The Journal of infectious diseases,
David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
August 2021, Vaccines,
David W Wright, and Ilona P Deuzing, and Philippe Flandre, and Peter van den Eede, and Micheline Govaert, and Laurentia Setiawan, and Peter V Coveney, and Anne-Geneviève Marcelin, and Vincent Calvez, and Charles A B Boucher, and Nancy Beerens
August 2003, Current opinion in investigational drugs (London, England : 2000),
Copied contents to your clipboard!